Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Active not recruiting 5Recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Salivary Gland Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 196Cisplatin 188Magnetic Resonance Spectroscopy 167Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 117Paclitaxel 112Oxaliplatin 110Biopsy 105venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 69sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × trastuzumab biosimilar HLX02 × Clear all
NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

University of Washington

Phase 2 Recruiting
25 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05408845 2026-05-04

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NRG Oncology

Phase 2 Recruiting
146 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡